Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2022 results: revenue $103.1 million, net income $16.6 million, EPS $0.14 per diluted common share. Guidance reaffirmed.
- Period
- the quarter and year ended December 31, 2022
- Revenue
- $103.1 million
- Net income
- $16.6 million
- EPS
- $0.14 per diluted common share
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Fourth quarter revenue of $103.1 million, compared to $98.8 million in fourth quarter 2021 • 2022 revenue of $401.9 million, compared to $366.0 million in 2021 • 2023 revenue guidance of $430 – $450 million • Fourth quarter diluted net income per common share of $0.14, compared to $0.26 in fourth quarter 2021 • 2022 diluted net income per common share of $0.87, compared to $0.89 in 2021 • Cash and investments of $436.6 million, compared to $335.8 million at December 31, 2021 Corcept’s fourth quarter 2022 revenue was $103.1 million, compared to $98.8 million in the fourth quarter of 2021. Revenue for the full year was $401.9 million, compared to $366.0 million in 2021. The company expects 2023 revenue of $430 – $450 million. Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021. For the full year, it was $101.4 million compared to $112.5 million in 2021. Cash and investments of $436.6 million at December 31, 2022 compared to
View on SEC.gov